[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"plantar-fasciitis-chronic\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:plantar-fasciitis-chronic":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,6,0,[8,47,81,105,133,160],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":29,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":41,"leadSponsor":43,"locationsCount":46},"100641348","comparative-effectiveness-of-different-neural-mobilization-techniques-in-plantar-fasciitis-100641348",false,"NCT07657533","Comparative Effectiveness of Different Neural Mobilization Techniques in Plantar Fasciitis","Comparative Effectiveness of Different Neural Mobilization Techniques in Plantar Fasciitis: A Randomized Controlled Trial","RCT","Inclusion Criteria:\n\n* Anyone between the ages of 18 and 50\n* plantar heel pain for six weeks or more was eligible to participate.","ALL","18 Years","50 Years",{"count":21,"type":22},60,"ESTIMATED","INTERVENTIONAL",[25],"NA","BThis study will be designed to compare between the effect of adding posterior tibial nerve or saphenous nerve mobilization to the traditional physical therapy on pain intensity, foot function, pressure pain threshold, ankle dorsiflexion ROM and central sensitization in patients with PF.",[28],"Plantar Fasciitis, Chronic",[30,31,32,33],"plantar fasciopathy","neural mobilization","conventional therapy","central sensitization","NOT_YET_RECRUITING","2026-06-14",{"date":37,"type":38},"2026-06-18","ACTUAL",{"date":40,"type":22},"2026-07-01",{"date":42,"type":22},"2026-10-01",{"name":44,"class":45},"Prince Sattam Bin Abdulaziz University","OTHER",1,{"id":48,"slug":49,"hasResults":11,"nctId":50,"briefTitle":51,"officialTitle":52,"acronym":4,"eligibilityCriteria":53,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":54,"enrollmentInfo":55,"targetDuration":4,"studyType":23,"phases":57,"briefSummary":58,"conditions":59,"keywords":63,"overallStatus":71,"whyStopped":4,"lastUpdateSubmitDate":72,"lastUpdatePostDateStruct":73,"startDateStruct":75,"completionDateStruct":77,"leadSponsor":79,"locationsCount":46},"100638228","barefoot-walking-vs-standardised-conservative-care-for-plantar-fasciopathy-100638228","NCT07600229","Barefoot Walking VS Standardised Conservative Care for Plantar Fasciopathy","Clinical and Economic Effectiveness of Barefoot Walking Compared to Standardised Conservative Care for the Treatment of Plantar Fasciopathy: a Pragmatic Randomised Controlled Trial","Inclusion Criteria:\n\n* Aged 18-70 years;\n* Clinical diagnosis of Plantar Fasciopahty, defined by: a) Pain localised to the medial calcaneal tubercle of sharp or stabbing quality; b) Pain worst with the first few steps in the morning or after a period of rest (first-step pain); c) Pain reproduced with palpation of the medial calcaneal tubercle OR positive Windlass Test;\n* Symptom duration greater than 4 weeks;\n* Able to walk independently without a mobility aid\n* Able to provide informed consent and comply with study protocol\n\nExclusion Criteria:\n\n* Prior surgery on the affected foot\n* Diabetes with peripheral neuropathy or other neurological condition affecting lower limb sensation or motor control\n* Active inflammatory arthropathy, uncontrolled vascular disease, or inability to walk unaided\n* Current or recent (less than 6 months) bony stress fracture or other acute foot or ankle injury on the affected side\n* Pregnancy during the intervention period\n* BMI greater than 40 kg\u002Fm²\n* Corticosteroid injection to the affected foot within the previous 3 months\n* Night splints initiated less than 4 weeks prior to enrolment\n* Any condition that would make participation unsafe, including open foot wounds","70 Years",{"count":56,"type":22},74,[25],"The goal of this clinical trial is to learn if a barefoot walking programme can treat plantar fasciopathy (heel pain) in adults aged 18-70. The main questions it aims to answer are:\n\n* Does a barefoot walking programme reduce heel pain compared to a standardised stretching and strengthening programme?\n* Does a barefoot walking programme improve foot function and quality of life in adults with plantar fasciopathy?\n\nResearchers will compare a barefoot walking programme to a standardised stretching and strengthening programme to see if barefoot walking is an effective conservative management approach for plantar fasciopathy.\n\nParticipants will:\n\n* Be randomly assigned to either a barefoot walking programme or a stretching and strengthening programme\n* Complete a 12-week home-based exercise programme\n* Complete short weekly questionnaires throughout the 12 weeks\n* Complete 3 follow-up surveys over 6 months after the intervention ends\n* Receive education on load management and plantar fasciopathy",[60,61,28,62],"Plantar Fasciopathy","Plantar Fasciitis","Heel Pain",[64,65,66,67,68,69,70],"Plantar fasciopathy","Plantar fasciitis","Heel pain","Barefoot walking","Foot pain","Musculoskeletal","Physical therapy","RECRUITING","2026-05-20",{"date":74,"type":38},"2026-05-22",{"date":76,"type":38},"2026-05-07",{"date":78,"type":22},"2027-10-31",{"name":80,"class":45},"Elisabetta Brigo",{"id":82,"slug":83,"hasResults":11,"nctId":84,"briefTitle":85,"officialTitle":85,"acronym":86,"eligibilityCriteria":87,"healthyVolunteers":88,"sex":17,"minAge":18,"maxAge":18,"enrollmentInfo":89,"targetDuration":4,"studyType":23,"phases":91,"briefSummary":92,"conditions":93,"keywords":94,"overallStatus":71,"whyStopped":4,"lastUpdateSubmitDate":96,"lastUpdatePostDateStruct":97,"startDateStruct":99,"completionDateStruct":101,"leadSponsor":103,"locationsCount":46},"100636601","sensitivity-and-tests-for-evaluation-of-plantar-fasciopathy-100636601","NCT07567807","Sensitivity and Tests for Evaluation of Plantar Fasciopathy","STEP","Inclusion Criteria:\n\n* PF group:\n\n  * Patients on the waiting list at Clinic I of the Rizzoli Orthopaedic Institute for surgical intervention with a diagnosis of recalcitrant PF lasting at least 12 months\n  * Age \\>18 years\n  * MRI of the foot and ankle negative for other local causes of pain included in the differential diagnosis of PF\n  * Negative electromyography for tarsal tunnel syndrome\n* Control group:\n\n  * Age \\>18 years\n  * Outpatients followed at Clinic I for conditions unrelated to the foot and ankle, with no clinical history of foot pain or pathology in the preceding 12 months\n\nExclusion Criteria:\n\n* PF and control groups:\n\n  * Minor patients\n  * Patients with diagnosed rheumatologic diseases currently under pharmacological treatment\n  * Patients with diabetes or diabetic neuropathy\n  * Pregnant women",true,{"count":90,"type":22},45,[25],"Plantar fasciopathy (PF), one of the leading causes of foot pain, affects up to one in ten individuals in their lifetime. Characterized by pain and structural alterations at the proximal insertion of the plantar fascia on the calcaneus, the term \"PF\" has replaced \"plantar fasciitis,\" as degenerative tissue changes predominate over inflammatory processes.\n\nThe pathogenesis of PF remains incompletely understood but appears to involve the gastrocnemius muscle, which is part of an integrated biomechanical unit including the calcaneus and the plantar fascia. Diagnosis is primarily based on clinical history and physical examination, while imaging modalities such as ultrasound and magnetic resonance imaging assist in excluding differential diagnoses. A simple clinical test to distinguish PF from other causes of heel pain, such as plantar fat pad syndrome or Baxter's nerve entrapment, could improve diagnostic efficiency.\n\nGiven the biomechanical relationship between the Achilles tendon and the plantar fascia, and their shared association with gastrocnemius tightness, a clinical test adapted from Achilles tendon assessment may be useful for diagnosing PF. In 2003, the Royal London Hospital proposed a diagnostic approach for Achilles tendinopathy based on pain reduction during active ankle dorsiflexion, which reduces tension in the tendon. The same concept could be applied, with appropriate modifications, to PF.\n\nThe present study aims to evaluate the sensitivity, specificity, reproducibility, and predictive value of localized tenderness at the medial calcaneal tuberosity and of a modified version of the Royal London Hospital Test in patients with PF. Secondarily, it will assess the reproducibility and prevalence of the Silfverskiöld test, supporting the concept of a biomechanical unit involving the triceps surae, calcaneus, and plantar fascia.\n\nAim of this study is to evaluate the sensitivity, specificity, reproducibility, and predictive value of tenderness at the medial calcaneal tuberosity and of a modified version of the Royal London Hospital Test in patients presenting with clinical signs of PF. The modified version of the Royal London Hospital Test for PF has not yet been formally validated in the literature. However, the study was designed following the methodology adopted by Prof. Maffulli for the validation of the original test. Therefore, this is an exploratory study aimed at collecting preliminary data on this new diagnostic test. The secondary objectives of this study is to evaluate the reproducibility and prevalence of the Silfverskiöld test in the study population.",[28],[30,95],"Silfverskiöld test","2026-04-28",{"date":98,"type":38},"2026-05-05",{"date":100,"type":38},"2025-04-01",{"date":102,"type":22},"2026-09-30",{"name":104,"class":45},"Istituto Ortopedico Rizzoli",{"id":106,"slug":107,"hasResults":11,"nctId":108,"briefTitle":109,"officialTitle":110,"acronym":111,"eligibilityCriteria":112,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":113,"targetDuration":4,"studyType":115,"phases":4,"briefSummary":116,"conditions":117,"keywords":121,"overallStatus":71,"whyStopped":4,"lastUpdateSubmitDate":123,"lastUpdatePostDateStruct":124,"startDateStruct":126,"completionDateStruct":128,"leadSponsor":130,"locationsCount":132},"100635890","evaluation-of-platelet-rich-plasma-prp-treatment-in-tendinopathies-100635890","NCT07558564","Evaluation of Platelet-Rich Plasma (PRP) Treatment in Tendinopathies","Multicenter Real-World Evidence (RWE) Study: Evaluation of Platelet-Rich Plasma (PRP) Treatment in Tendinopathies","RWE-TDP-PRP","Inclusion Criteria:\n\n* Clinical and\u002For ultrasound diagnosis of chronic tendinopathy (duration \\>6 weeks)\n* Age \\>18 years\n* Provision of written informed consent\n* Willingness and ability to complete follow-up assessments for 12 months\n\nExclusion Criteria:\n\n* Surgical treatment of the affected tendon within the previous 6 months\n* Corticosteroid injection within the last month\n* Systemic inflammatory disease (e.g., rheumatoid arthritis)\n* Coagulopathies or ongoing anticoagulant therapy\n* Complete blood count showing a platelet concentration \\\u003C100 × 10⁹\u002FL (to exclude patients with potential thrombocytopenia)\n* Pregnancy or breastfeeding",{"count":114,"type":22},2000,"OBSERVATIONAL","This multicenter, prospective, observational study, based on real-world evidence (RWE), aims to evaluate the efficacy and safety of Platelet-Rich Plasma (PRP) treatment across four types of tendinopathies: patellar, Achilles, epicondylar, and plantar fasciosis. Data collection and analysis will be conducted using the BioSmartData® platform, including hematology analyzers for PRP characterization, clinical variables, treatment protocols, and longitudinal assessment of therapeutic response.",[118,119,120,28],"Patellar Tendinopathy","Achilles Tendinopathy (AT)","Epicondylitis, Lateral",[122],"tendinopathy, Real World Evidence (RWE), platelet-rich plasma, plantar fasciosis, epicondylitis, patellar tendon, Achilles tendon","2026-04-23",{"date":125,"type":38},"2026-04-30",{"date":127,"type":22},"2026-04",{"date":129,"type":22},"2028-03",{"name":131,"class":45},"ReSport Clinic",5,{"id":134,"slug":135,"hasResults":11,"nctId":136,"briefTitle":137,"officialTitle":138,"acronym":4,"eligibilityCriteria":139,"healthyVolunteers":11,"sex":17,"minAge":140,"maxAge":141,"enrollmentInfo":142,"targetDuration":4,"studyType":23,"phases":144,"briefSummary":146,"conditions":147,"keywords":148,"overallStatus":71,"whyStopped":4,"lastUpdateSubmitDate":150,"lastUpdatePostDateStruct":151,"startDateStruct":153,"completionDateStruct":155,"leadSponsor":157,"locationsCount":46},"100623322","phase-1-lateral-plantar-artery-embolization-for-plantar-fasciitis-100623322","NCT07395128","Lateral Plantar Artery Embolization For Plantar Fasciitis","Lateral Plantar Artery Embolization to Treat Pain Chronic Heel Pain Due To Plantar Fasciitis A Pilot Study to Assess Feasibility","Inclusion Criteria:\n\n* Age ≥ 25 years\n* Subject provides written informed consent\n* Patient with Plantar Fasciitis refractory to 3 months of conservative management\n* Self reported pain of at least 4\u002F10 on visual analog scale (VAS)\n* Non-surgical candidate\u002Flooking to avoid surgery\n\nExclusion Criteria:\n\n* Heel pain caused by acute fracture, recent trauma, inflammatory conditions, muscle\u002Fligament injury, and etiologies related to bone mineral density.\n* Steroid injection in the last 90 days from the embolization procedure\n* Known severe allergy to Lipiodol and\u002For iodinated contrast media\n* Diagnosis of peripheral arterial disease affecting the lower extremities\n* Pregnancy or breastfeeding\n* Anticoagulation or irreversible coagulopathy\n* GFR \\\u003C45 or Serum creatinine \\> 2.0 mg\u002Fdl\n* Type 1 Diabetes Mellitus","25 Years","80 Years",{"count":143,"type":22},10,[145],"PHASE1","The goal of this clinical trial is to learn if lateral plantar artery embolization using Lipiodol can safely and effectively treat chronic heel pain due to plantar fasciitis in adults aged 25 to 80. The main questions it aims to answer are:\n\nDoes this procedure successfully reduce chronic heel pain as measured by the Visual Analog Scale (VAS) over 12 months?\n\nHow safe is the procedure, specifically regarding the frequency of serious medical problems or adverse events related to the device?\n\nParticipants will:\n\nUndergo a minimally invasive procedure where a doctor uses a small tube (catheter) to inject a temporary blocking agent (LipioJoint) into specific blood vessels in the foot.\n\nReceive a phone call one day after the procedure to check for early side effects.\n\nParticipate in four follow-up telehealth visits over the course of one year (at 1, 3, 6, and 12 months).\n\nComplete pain intensity surveys (VAS) and report any changes in their use of other therapies or medications during these visits.",[28,61],[149],"plantar fasciitis","2026-02-05",{"date":152,"type":38},"2026-02-09",{"date":154,"type":38},"2025-12-20",{"date":156,"type":22},"2027-03",{"name":158,"class":159},"Joint & Vascular Institute","INDUSTRY",{"id":161,"slug":162,"hasResults":11,"nctId":163,"briefTitle":164,"officialTitle":164,"acronym":4,"eligibilityCriteria":165,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":166,"enrollmentInfo":167,"targetDuration":4,"studyType":23,"phases":169,"briefSummary":170,"conditions":171,"keywords":4,"overallStatus":71,"whyStopped":4,"lastUpdateSubmitDate":172,"lastUpdatePostDateStruct":173,"startDateStruct":175,"completionDateStruct":177,"leadSponsor":179,"locationsCount":46},"100537989","acupuncture-of-different-treatment-frequency-in-chronic-plantar-fasciitis-100537989","NCT06284993","Acupuncture of Different Treatment Frequency in Chronic Plantar Fasciitis","Inclusion Criteria:\n\n* Patients with a diagnosis of chronic PF with a disease course of ≥ 6 months;\n* The most painful heel pain in the morning is Visual Analogue Scale (VAS; 0 indicating no pain and 100 indicating maximal pain) ≥ 40 mm on a 100 mm VAS;\n* Patients between the ages of 18 and 75 years;\n* Patients should be conscious, free from mental disorders, and without serious heart, liver, or kidney diseases; and\n* Willing to sign the informed consent form.\n\nExclusion Criteria:\n\n* History of calcaneal tuberosity fracture\u002Fcalcaneal stress fracture\u002Fcalcaneal contusion\u002Fplantar fascia rupture;\n* History of ankle or foot surgery;\n* Achilles tendon enthesis lesion\u002Ftarsal tunnel syndrome\u002Fmedial calcaneal nerve entrapment\u002Fnerve injury;\n* Systemic or local infection, severe cracked heel, foot deformity (e.g., high arched feet, flat feet, foot valgus);\n* Systemic diseases (e.g., obligatory spondylitis, rheumatoid arthritis, seronegative arthritis, autoimmune system diseases, tumors, diabetes ) and other situations judged by the investigators not to be suitable for the clinical trial;\n* Pregnant women; patients with severe combined cardiac, hepatic, renal, hematopoietic, and patients with cardiac pacemakers , and patients with severe poor general nutritional status;\n* Cognitive impairment, inability to understand the content of the scale evaluation;\n* Topical steroid injection or oral use in the past 6 months;\n* Patients with a known fear of acupuncture or who have been treated with acupuncture in the past 8 weeks.","75 Years",{"count":168,"type":22},80,[25],"Plantar fasciitis (PF) is one of the most common causes of heel pain, typically characterized by a sharp pain in the plantar aponeurosis, specifically near the insertion site close to the medial process of the calcaneal tuberosity. It has been reported that 1 in 10 people are expected to be affected by PF in their lifetime. A comprehensive internet-panel survey conducted among the adult United States population revealed the population-based prevalence of self-reported PF with pain in the last month was 0.85 percent. Approximately 1 million patients are diagnosed with this disease each year in the United States. PF was believed to be an acute inflammatory disease, but patient samples show it is actually a chronic degenerative process caused by various factors such as repetitive stresses, vascular and metabolic disorders, excess free radicals, high temperatures, genetic factors, and conditions like rheumatoid arthritis and spondyloarthropathies. PF may be associated with impaired health-related quality of life, including reduced life functioning, poor perceived health status and social isolation. Additionally, a recent study indicates that the annual cost associated with PF is $284 million.\n\nThe first-line treatments recommended by guidelines for PF encompass physical therapy (including manual therapy, stretching, and others), pharmacological therapy (involving corticosteroids or platelet-rich plasma), and surgical treatment. However, the definite effects of physical therapy still require confirmation. Pharmacological treatments, such as local corticosteroid injections, exhibit a short maintenance period. Some studies indicate that the relief provided by corticosteroid injections lasts up to one month, yet its efficacy diminishes after 6 months. Surgical treatment is generally advised 6 to 12 months after unsuccessful conservative treatment, albeit with the drawback of higher costs, post-surgery recovery time, and patient apprehension.\n\nAcupuncture is one of the most common complementary alternative therapy for the treatment of pain-related diseases such as musculoskeletal muscle, and recent guidelines recommend dry needling as a treatment for relief of plantar fasciitis, with a level of evidence of B. Dry acupuncture is different from acupuncture in terms of theoretical basis, therapeutic apparatus, technical operation and scope of indications, however, the American Alliance for Professional Acupuncture Safety also believes that dry needling falls under the umbrella of acupuncture, but under a different name. In addition, there are systematic evaluations that suggest acupuncture can be a safe and effective treatment for PF, and most of the trials in the systematic evaluations used 4-week treatment courses. Our prior study demonstrated that a 4-week intervention of both electroacupuncture and manual acupuncture resulted in improved pain outcomes among patients with PF.\n\nThe frequency of acupuncture stands as a crucial factor influencing its efficacy. A study revealed that needling trials with negative results had a significantly lower frequency compared to those yielding positive results. Furthermore, several studies indicate that acupuncture once a week can be help in conditions such as simple obesity, functional dyspepsia, and overactive bladder in women. There is no universally accepted standard of frequency of treatment for many conditions, including PF. In China, patients with chronic diseases usually receive 3-5 acupuncture treatments per week. However, in most previous trials, individuals with chronic diseases received 1-2 needling sessions per week. An increase in the frequency of acupuncture means an increase in the pain, time, and financial investment associated with the acupuncture process. Therefore, it is critical to optimize the frequency of acupuncture to ensure the effectiveness and feasibility of the treatment while avoiding increasing the burden on the patient. Accordingly, the investigators designed the current trial to compare the effects of different acupuncture sessions (1 session per week versus 3 sessions per week) in a randomized controlled trial (RCT) of chronic PF. The hypothesis is that 1 session per week compared with 3 sessions per week of electroacupuncture treatment over a total of 4 weeks of treatment will provide a similar effect on pain relief in chronic PF.",[28],"2025-07-13",{"date":174,"type":38},"2025-07-16",{"date":176,"type":38},"2024-05-21",{"date":178,"type":22},"2026-12-30",{"name":180,"class":45},"Guang'anmen Hospital of China Academy of Chinese Medical Sciences"]